On this page
Congenital stationary night blindness
This group of genetic disorders affects how light signals are processed in the retina, leading to persistent problems with night vision and often other visual symptoms. The condition typically does not worsen over time and most affected individuals retain useful daytime vision throughout life.
Overview
Congenital stationary night blindness represents a collection of inherited retinal disorders that share a common feature: impaired vision in low-light conditions present from birth or very early in life. The term 'stationary' reflects that the condition generally remains stable rather than progressively worsening, distinguishing it from degenerative retinal diseases. Affected individuals typically describe significant difficulty adapting to darkness, such as when entering a dimly lit room or navigating outdoors after sunset.
The underlying problem involves disruption of the signal transmission pathway in the retina, specifically affecting how rod photoreceptors communicate visual information to downstream cells. Rod photoreceptors are specialised cells responsible for vision in low light, and when the signalling cascade between rods and other retinal cells is impaired, night vision suffers whilst daytime vision may remain relatively preserved. Research suggests that several different genes can cause congenital stationary night blindness, each affecting distinct components of this retinal signalling system. The condition is rare, though exact prevalence figures are not well established in the UK population.
Symptoms & clinical features
The hallmark symptom is nyctalopia, the medical term for night blindness, which manifests as marked difficulty seeing in dim environments. Parents often notice that affected children struggle to navigate in darkened rooms, appear hesitant when lighting conditions change, or have trouble with activities at dusk or night-time. People with this condition show minimal or no improvement in their ability to see in low light even after prolonged exposure, whereas those with typical vision adapt to darkness within minutes.
Additional features vary depending on the specific genetic cause and subtype. Some affected individuals experience myopia, reduced visual acuity that may not fully correct with standard glasses, or nystagmus. Colour vision is typically preserved in most forms of the condition. Certain subtypes are associated with specific findings on ophthalmological examination, such as a distinctive appearance of the retina called a Mizuo-Nakamura phenomenon, though this is not present in all cases. Day-to-day visual function in well-lit environments is often surprisingly good, allowing most affected people to read, drive during daylight hours, and perform detailed tasks without significant limitation.
Video: Genetics 101
Affected organs
The condition exclusively affects the eyes, specifically the retina, which is the light-sensitive tissue lining the back of the eye. Within the retina, the disorder disrupts communication between rod photoreceptors and bipolar cells, an essential step in transmitting visual signals toward the brain. This selective involvement of the retinal signalling pathway means that other body systems remain unaffected. The structural integrity of the eye itself is generally preserved, with the retinal architecture remaining intact in most forms of the condition, distinguishing it from degenerative retinal diseases where photoreceptor loss occurs over time.
Risks & severity
The severity of night vision impairment can range from moderate difficulty in low light to near-complete inability to see in darkness. However, the condition remains stable throughout life in the vast majority of cases, meaning that visual function does not deteriorate with age. This non-progressive nature is an important distinguishing feature and provides reassurance to affected individuals and their families.
Most people with congenital stationary night blindness maintain useful daytime vision and can lead independent lives with appropriate adaptations. The primary impact relates to activities requiring vision in dim conditions, such as evening driving, navigating unfamiliar places at night, or certain occupational tasks. Some individuals may experience additional challenges related to reduced visual acuity or myopia, though these features are manageable with corrective lenses in many cases. Serious complications are uncommon, and the condition does not typically affect life expectancy or general health.
Genetic causes
Congenital stationary night blindness results from pathogenic variants in genes essential for retinal signal transmission. Three causative genes are well characterised: CACNA1F, GRM6, and NYX. Each encodes a protein critical to the pathway by which visual information flows from rod photoreceptors to other retinal cells.
CACANA1F encodes a calcium channel subunit that helps regulate neurotransmitter release from photoreceptors. When pathogenic changes disrupt this channel, the controlled release of chemical signals to downstream retinal cells becomes impaired. GRM6 produces a receptor on bipolar cells that receives glutamate signals from photoreceptors; variants affecting this receptor prevent proper signal detection. NYX encodes nyctalopin, a protein that helps organise the molecular machinery at the synapse between photoreceptors and bipolar cells, ensuring efficient signal transfer.
These genes all contribute to the same functional pathway, explaining why variants in different genes produce similar clinical pictures. The shared mechanism involves breakdown of communication at the first synapse of the visual system, preventing rod-generated signals from being effectively transmitted onward for processing, whilst the rod cells themselves remain structurally intact.
- CACNA1F calcium voltage-gated channel subunit alpha1 F
- GRM6 glutamate metabotropic receptor 6
- NYX nyctalopin
Inheritance pattern
Congenital stationary night blindness follows an autosomal recessive inheritance pattern for the genes included in this reference dataset. This means an affected individual has inherited pathogenic variants in both copies of the causative gene, one from each parent. Parents who each carry a single pathogenic variant typically have normal vision themselves, as one working gene copy is sufficient for proper retinal function.
When both parents are carriers, each pregnancy has a 25 per cent chance of producing an affected child, a 50 per cent chance of producing a carrier child with normal vision, and a 25 per cent chance of producing a child who neither carries nor is affected by the familial variants. Siblings of an affected individual have a two-in-three chance of being carriers if they are unaffected. Genetic counselling can help families understand these risks and explore options for family planning.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis typically begins when an individual or family members notice persistent difficulty with night vision, prompting referral to an ophthalmologist or optometrist. Clinical examination may reveal characteristic findings on electroretinography, a test that measures electrical responses of retinal cells to light stimulation. The specific pattern of electrical activity helps distinguish congenital stationary night blindness from progressive retinal conditions and can suggest particular subtypes.
Confirmatory genetic testing involves sequencing the known causative genes to identify pathogenic variants. Within the NHS Genomic Medicine Service, testing for inherited retinal disorders including congenital stationary night blindness is accessed through clinical genetics services, often using gene panel testing that examines multiple retinal disease genes simultaneously. An appropriate NHS R-code would be applied by the referring clinician to facilitate testing through the genomic laboratory network. Referral typically comes from ophthalmology services when the clinical presentation suggests an inherited basis, and genetic confirmation allows for accurate recurrence risk counselling and potential reproductive options.
Management & lifestyle
No curative treatment currently exists for congenital stationary night blindness, and management focuses on optimising remaining vision and implementing practical adaptations. Standard refractive correction with glasses or contact lenses addresses any associated myopia or refractive error. Low-vision aids may benefit some individuals, though many find that maximising ambient lighting and allowing extra time for activities in dim conditions provides sufficient accommodation.
Practical strategies include using brighter lighting at home, carrying a torch for navigating dark environments, and avoiding driving at night or in poor visibility conditions. Occupational guidance may be relevant for individuals whose work involves low-light environments. Regular ophthalmological review allows monitoring for any unexpected changes, though progression is not anticipated. Genetic counselling provides families with information about inheritance, recurrence risks, and reproductive options including preimplantation genetic testing where appropriate. Referral to specialist low-vision services through the NHS can provide additional support and adaptive equipment where needed.
UK care pathway
Within the NHS, individuals with suspected congenital stationary night blindness are typically referred from primary care or optometry to ophthalmology services for detailed assessment. When an inherited retinal disorder is suspected, referral onwards to clinical genetics services facilitates access to genetic testing through the NHS Genomic Medicine Service. Testing may utilise gene panels covering inherited retinal disorders, with analysis coordinated through regional genomic laboratory hubs. Genetic counsellors within clinical genetics services provide pre-test and post-test counselling, explaining inheritance patterns and supporting families in understanding results and implications for relatives.
Frequently asked questions
Will my vision get worse as I get older?
No, congenital stationary night blindness does not typically worsen with age. The term 'stationary' specifically indicates that the condition remains stable throughout life, unlike progressive retinal disorders where vision deteriorates over time.
Can I still drive with this condition?
Many people with congenital stationary night blindness can drive safely during daylight hours if their daytime vision meets DVLA standards. However, night driving is generally not advisable due to the significant difficulty seeing in low light, and you should discuss your specific situation with your ophthalmologist and inform the DVLA.
Will my children inherit this condition?
If you have autosomal recessive congenital stationary night blindness, your children would only be affected if your partner also carries a pathogenic variant in the same gene, which is uncommon. A genetic counsellor can assess your specific family situation and explain the risks in detail.
Are there any treatments that might help my night vision?
Currently, no medical treatments can restore normal night vision in congenital stationary night blindness. Management focuses on maximising your remaining vision through appropriate lighting, using low-vision aids where helpful, and making practical adaptations to daily activities in dim conditions.
Should my siblings be tested for this condition?
If you have congenital stationary night blindness, your siblings have a two-in-three chance of being carriers if they do not show symptoms. Genetic counselling can help your family understand testing options and whether carrier testing would be useful for family planning purposes.
References
- Katta M, de Guimaraes TAC, Fujinami-Yokokawa Y. Congenital Stationary Night Blindness: Structure, Function and Genotype-Phenotype Correlations in a Cohort of 122 Patients. Ophthalmology. Retina. 2024. PMID: 38522615
- Tsang SH, Sharma T. Congenital Stationary Night Blindness. Advances in experimental medicine and biology. 2018. PMID: 30578486
- Gottlob I. Nystagmus. Current opinion in ophthalmology. 2001. PMID: 11588502
- Irie S, Furukawa T. TRPM1. Handbook of experimental pharmacology. 2014. PMID: 24756714
- Adam MP, Bick S, Mirzaa GM. X-Linked Congenital Stationary Night Blindness. 1993. PMID: 20301423
- Cheong J, Tsang SH, Sharma T. Congenital Stationary Night Blindness. Advances in experimental medicine and biology. 2025. PMID: 40736815
- Kim AH, Liu PK, Chang YH. Congenital Stationary Night Blindness: Clinical and Genetic Features. International journal of molecular sciences. 2022. PMID: 36499293
- Koschak A, Fernandez-Quintero ML, Heigl T. Cav1.4 dysfunction and congenital stationary night blindness type 2. Pflugers Archiv : European journal of physiology. 2021. PMID: 34212239